Effect of add-on hydroxychloroquine therapy on serum proinflammatory cytokine levels in patients with systemic lupus erythematosus.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
17 06 2022
Historique:
received: 13 12 2021
accepted: 08 06 2022
entrez: 17 6 2022
pubmed: 18 6 2022
medline: 22 6 2022
Statut: epublish

Résumé

We investigated the effect of hydroxychloroquine (HCQ) as an add-on treatment to immunosuppressants on the expression of proinflammatory cytokines in patients with systemic lupus erythematosus. Serum levels of tumor necrosis factor (TNF)-α, interleukin (IL)-2, IL-6, IL-8, vascular endothelial growth factor (VEGF)-A, monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1α (MIP-1α), and interleukin 1 receptor antagonist (IL-1ra) were measured immediately before and 3 months after treatment with oral HCQ. Among the 51 patients enrolled in the study, HCQ treatment led to significantly reduced serum levels of TNF-α, IL-6, IL-8, VEGF-A, IL-1ra, and IL-2 (p < 0.0001; p = 0.0006; p = 0.0460, p = 0.0177; p < 0.0001; p = 0.0282, respectively) and to decreased (but not significantly) levels of MIP-1α (p = 0.0746). No significant changes were observed in the serum MCP-1 levels before and after HCQ administration (p = 0.1402). Our results suggest that an add-on HCQ treatment modulates the expression of proinflammatory cytokines even in systemic lupus erythematosus patients with low disease activity.

Identifiants

pubmed: 35715525
doi: 10.1038/s41598-022-14571-6
pii: 10.1038/s41598-022-14571-6
pmc: PMC9205904
doi:

Substances chimiques

Chemokine CCL3 0
Cytokines 0
Interleukin 1 Receptor Antagonist Protein 0
Interleukin-6 0
Interleukin-8 0
Tumor Necrosis Factor-alpha 0
Vascular Endothelial Growth Factor A 0
Hydroxychloroquine 4QWG6N8QKH

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

10175

Informations de copyright

© 2022. The Author(s).

Références

Arthritis Res Ther. 2006;8(1):203
pubmed: 16542467
PLoS Pathog. 2009 Oct;5(10):e1000639
pubmed: 19876394
Clin Immunol. 2020 Jul;216:108461
pubmed: 32437924
BMC Cancer. 2018 Jun 22;18(1):678
pubmed: 29929491
Nat Med. 2012 Jun 06;18(6):871-82
pubmed: 22674006
Lupus. 2019 May;28(6):713-721
pubmed: 31046570
Arthritis Res Ther. 2018 Aug 9;20(1):173
pubmed: 30092845
Inflammopharmacology. 2018 Oct;26(5):1175-1182
pubmed: 29987550
Lupus. 2012 Jul;21(8):830-5
pubmed: 22343096
Arthritis Res Ther. 2012 Jun 27;14(3):R155
pubmed: 22734582
J Cell Physiol. 2017 Jul;232(7):1862-1871
pubmed: 27925202
Arthritis Res Ther. 2019 Dec 16;21(1):287
pubmed: 31842967
Z Rheumatol. 2017 May;76(4):357-363
pubmed: 27278779
Mediators Inflamm. 2014;2014:385297
pubmed: 25548434
Arthritis Rheumatol. 2014 Sep;66(9):2532-2544
pubmed: 24838349
J Cell Immunol. 2019;1(2):33-42
pubmed: 31984378
N Engl J Med. 2005 Dec 15;353(24):2550-8
pubmed: 16354891
Ann Rheum Dis. 2019 Jun;78(6):736-745
pubmed: 30926722
Lupus. 2019 Jun;28(7):826-833
pubmed: 31068068
J Invest Dermatol. 2005 Nov;125(5):889-94
pubmed: 16297185
Nat Rev Rheumatol. 2020 Mar;16(3):155-166
pubmed: 32034323
Arthritis Rheum. 2012 Aug;64(8):2677-86
pubmed: 22553077
Clin Immunol. 2018 Oct;195:1-7
pubmed: 29981383
Arch Dermatol. 2011 Feb;147(2):203-8
pubmed: 21339447
Biomark Med. 2018 Nov;12(11):1291-1302
pubmed: 30511585
Ann Rheum Dis. 2019 Feb;78(2):238-248
pubmed: 30563869
Autoimmun Rev. 2018 Jan;17(1):44-52
pubmed: 29108825
Inflammopharmacology. 2015 Oct;23(5):231-69
pubmed: 26246395
Ann Rheum Dis. 2019 Dec;78(12):1669-1676
pubmed: 31570366
Ann Rheum Dis. 2012 Nov;71(11):1771-82
pubmed: 22851469
Clin Exp Rheumatol. 2000 Sep-Oct;18(5):565-70
pubmed: 11072595
Mediterr J Rheumatol. 2017 Mar 28;28(1):13-19
pubmed: 32185249
Cytokine. 2021 Oct;146:155640
pubmed: 34252872
Arthritis Rheum. 1982 Nov;25(11):1271-7
pubmed: 7138600
PLoS One. 2016 Jul 26;11(7):e0159964
pubmed: 27458981
Int J Med Sci. 2020 Feb 4;17(4):498-509
pubmed: 32174780
Ann Rheum Dis. 2010 Jan;69(1):20-8
pubmed: 19103632
Arthritis Rheum. 2009 Oct;60(10):3098-107
pubmed: 19790071
Lupus. 2019 Nov;28(13):1524-1533
pubmed: 31660791
Clin Immunol. 2017 Dec;185:10-20
pubmed: 27498110
Lupus Sci Med. 2018 Jun 04;5(1):e000260
pubmed: 29955370
Mol Immunol. 2015 Oct;67(2 Pt B):223-32
pubmed: 26038301
Lupus. 2017 Dec;26(14):1517-1527
pubmed: 28467291
J Autoimmun. 2020 Jun;110:102374
pubmed: 31812331
Biomed Res Int. 2020 Feb 19;2020:7149408
pubmed: 32149126
Nat Rev Rheumatol. 2016 Nov 22;12(12):716-730
pubmed: 27872476
Cells. 2020 Apr 08;9(4):
pubmed: 32276504

Auteurs

Risa Wakiya (R)

Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan. wakiya.risa@kagawa-u.ac.jp.

Kiyo Ueeda (K)

Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan.

Shusaku Nakashima (S)

Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan.

Hiromi Shimada (H)

Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan.

Tomohiro Kameda (T)

Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan.

Mai Mahmoud Fahmy Mansour (MMF)

Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan.

Mikiya Kato (M)

Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan.

Taichi Miyagi (T)

Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan.

Koichi Sugihara (K)

Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan.

Mao Mizusaki (M)

Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan.

Rina Mino (R)

Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan.

Norimitsu Kadowaki (N)

Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan.

Hiroaki Dobashi (H)

Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH